Additional information
| Active substance | Paliperidone |
|---|---|
| Storage conditions | Store at room temperature away from moisture and heat |
| Side effects | Extrapyramidal symptoms (EPS), tachycardia, weight gain, dizziness, insomnia, constipation |
| Effects | Symptom reduction in schizophrenia and schizoaffective disorder |
| Dosage (sports) | Not applicable |
| Dosage (medical) | Typically starts at 3 mg per day, can be adjusted up to 12 mg per day based on clinical response |
| Half-life | Approximately 23 hours |
| Main action | Antagonist of serotonin type 2 (5HT2) and dopamine type 2 (D2) receptors |
| Substance class | Atypical antipsychotic |
| Formula | C23H27FN4O3 |
| Chemical name | 9-hydroxyrisperidone |
| Trade name | Invega |
| Blood pressure | Can cause orthostatic hypotension |
| WAREHOUSE | International Warehouse 2 |
| Also known as | Paliperidone |
| Lab Test | Monitoring plasma levels not typically required but may be performed to ensure therapeutic levels |
| Aromatization | No |
| Hepatotoxicity | No |
| HBR | No |
| Water Retention | No |
| Acne | No |
| Classification | Antipsychotic |
| Use in sports | None |
| Manufacturer | Janssen-Cilag |
Reviews
There are no reviews yet.